Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

• Published in: Haematologica (Roma) Vol. 109; no. 2; pp. 401 - 410
• Main Authors: Dillon, Laura W., Higgins, Jake, Nasif, Hassan, Othus, Megan, Beppu, Lan, Smith, Thomas H., Schmidt, Elizabeth, Valentine III, Charles C., Salk, Jesse J., Wood, Brent L, Erba, Harry P., Radich, Jerald P., Hourigan, Christopher S.
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.02.2024; Ferrata Storti Foundation
• Subjects: Acute Myeloid Leukemia; Adult; Flow Cytometry - methods; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - therapy; Neoplasm, Residual - diagnosis; Prognosis; Recurrence; Treatment Outcome
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2023.283520

The presence of measurable residual disease (MRD) is strongly associated with treatment outcomes in acute myeloid leukemia (AML). Despite the correlation with clinical outcomes, MRD assessment has yet to be standardized or routinely incorporated into clinical trials and discrepancies have been observed between different techniques for MRD assessment. In 62 patients with AML, aged 18-60 years, in first complete remission after intensive induction therapy on the randomized phase III SWOG-S0106 clinical trial (clinicaltrials gov. Identifier: NCT00085709), MRD detection by centralized, high-quality multiparametric flow cytometry was compared with a 29-gene panel utilizing duplex sequencing (DS), an ultrasensitive next-generation sequencing method that generates double-stranded consensus sequences to reduce false positive errors. MRD as defined by DS was observed in 22 (35%) patients and was strongly associated with higher rates of relapse (68% vs. 13%; hazard ratio [HR] =8.8; 95% confidence interval [CI]: 3.2-24.5; P<0.001) and decreased survival (32% vs. 82%; HR=5.6; 95% CI: 2.3-13.8; P<0.001) at 5 years. DS MRD strongly outperformed multiparametric flow cytometry MRD, which was observed in ten (16%) patients and marginally associated with higher rates of relapse (50% vs. 30%; HR=2.4; 95% CI: 0.9-6.7; P=0.087) and decreased survival (40% vs. 68%; HR=2.5; 95% CI: 1.0-6.3; P=0.059) at 5 years. Furthermore, the prognostic significance of DS MRD status at the time of remission for subsequent relapse was similar on both randomized arms of the trial. These findings suggest that next-generation sequencing-based AML MRD testing is a powerful tool that could be developed for use in patient management and for early anti-leukemic treatment assessment in clinical trials.